CN105348270B - A kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp - Google Patents
A kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp Download PDFInfo
- Publication number
- CN105348270B CN105348270B CN201510753452.1A CN201510753452A CN105348270B CN 105348270 B CN105348270 B CN 105348270B CN 201510753452 A CN201510753452 A CN 201510753452A CN 105348270 B CN105348270 B CN 105348270B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- compound
- preventing
- tooth body
- dental pulp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
The present invention relates to a kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp, described pharmaceutical composition includes the compound and pharmaceutically acceptable carrier of effective dose, and the compound has having structure：
Description
Technical field
The present invention relates to field of medicaments, and specifically, the present invention relates to a kind of drug regimen for preventing and treating tooth body infections of dental pulp
Thing.
Background technology
Often cause infection in tooth body endodontic treatment, infection is common clinical frequently-occurring disease, and the cause of disease is more by the micro- life of cause of disease
Caused by thing infection, oral cavity causes the pathogenic bacteria of infection a lot, it has been investigated that, detected in the secretion in infection oral cavity more
Kind pathogenic bacteria, find one of serratia marcescens ATCC 14041 and pathogenic bacteria therein in the recent period.
The content of the invention
It is an object of the invention to provide a kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp.
In order to realize the purpose of the present invention, the present invention provides a kind of compound for preventing and treating tooth body infections of dental pulp, the compound
With having structure：
The present invention also provides a kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp, and described pharmaceutical composition includes effective dose
Compound and pharmaceutically acceptable carrier, the compound has having structure：
Preferably, the pharmaceutically acceptable carrier is diluent, disintegrant, adhesive, lubricant, stabilizer or rectified
Positive agent.
Preferably, the diluent is sugar derivatives, starch derivatives or cellulose derivative.
Preferably, the diluent is lactose.
Preferably, described pharmaceutical composition is powder, fine granule, granule, capsule or tablet.
The present invention also provides purposes of the compound in the medicine for preparing preventing and treating tooth body infections of dental pulp, under the compound has
Array structure：
Preferably, the infection is as caused by serratia marcescens ATCC 14041.
The present invention also provides purposes of the compound in the external medicine for suppressing serratia marcescens ATCC 14041 is prepared,
The compound has having structure：
Term " pharmaceutically acceptable " used herein refer to the biological activity that does not eliminate compound as described herein or
The material of property, such as carrier or diluent.This kind of material, which is applied to individual, does not cause undesirable biological action or not
With harmful way with being interacted comprising any component in its composition.
Term " pharmaceutically acceptable carrier " as used herein includes any and all solvent, decentralized medium, bag
Clothing material, surfactant, antioxidant, preservative (such as antiseptic, antifungal agent), isotonic agent, absorption delaying agent, salt,
Preservative, drug stabilizing agent, adhesive, excipient, disintegrant, lubricant, sweetener, flavouring, dyestuff etc. and its combination, this
It is well-known to those skilled in the art (for example, see Remington ' s Pharmaceutical Sciences, 18th
Ed.Mack Printing Company, 1990, pp.1289-1329).In addition to the carrier incompatible with active component, controlling
Consider to use any conventional carrier in treatment or pharmaceutical composition.
The compound of the present invention can be developed into clinically effective new for causing the pathogen significant effect of infection
Pharmaceutical composition.
Embodiment
Below by way of the description of embodiment, the invention will be further described, but this is not the limit to the present invention
System, those skilled in the art according to the present invention basic thought, various modifications may be made or improve, but without departing from this
The basic thought of invention, within the scope of the present invention.
Purposes of the experimental example the compounds of this invention in the external medicine for suppressing serratia marcescens ATCC 14041 is prepared
Research
Bacteriostatic test
Using following compounds, bacteriostatic test is carried out using filter paper enzyme classical in this area, wherein：
The structural formula of target compound is：
Shanghai Bei Nuo bio tech ltd is purchased from for examination strain serratia marcescens ATCC 14041.
Nutrient solution
Nutrient agar and nutrient broth, purchased from Chen Yu experimental facilities Co., Ltd of BeiJing ZhongKe.
Test method
Serratia marcescens ATCC 14041 is inoculated on agar plate nutrition fluid level, uniformly gathered during inoculation.
0.03 gram of target compound is weighed, adds 6000 milliliters of sterilized waters, the micropore filter of ultrasound 30 minutes, then 0.22 μm
Membrane filtration, obtain solution.The sterile circular filter paper piece of tweezer, above-mentioned solution is sprayed to complete wetting, be attached to the fine jade of inoculated bacteria
On fat flat board nutrition fluid level.Agar plate is placed in 37 DEG C of incubator, incubated 4 hours.Measure the diameter of antibacterial ring size.Survey
Determine to average for 3 times.
1.4 result
The average diameter of serratia marcescens ATCC 14041 antibacterial ring size is 13.68mm, and this shows that target compound has
There is extremely strong external suppression serratia marcescens ATCC 14041 effect.
Claims (1)
1. purposes of the compound in the medicine for preparing preventing and treating tooth body infections of dental pulp, it is characterised in that the compound has following
Structure：
The infection is as caused by serratia marcescens ATCC 14041.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510753452.1A CN105348270B (en) | 2015-11-09 | 2015-11-09 | A kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510753452.1A CN105348270B (en) | 2015-11-09 | 2015-11-09 | A kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105348270A CN105348270A (en) | 2016-02-24 |
| CN105348270B true CN105348270B (en) | 2018-01-09 |
Family
ID=55324353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510753452.1A Expired - Fee Related CN105348270B (en) | 2015-11-09 | 2015-11-09 | A kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105348270B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015113452A1 (en) * | 2014-01-29 | 2015-08-06 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| CN105153131A (en) * | 2015-09-21 | 2015-12-16 | 马彦丽 | Medicine combination for treating human neuroglioma during nursing |
-
2015
- 2015-11-09 CN CN201510753452.1A patent/CN105348270B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015113452A1 (en) * | 2014-01-29 | 2015-08-06 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| CN105153131A (en) * | 2015-09-21 | 2015-12-16 | 马彦丽 | Medicine combination for treating human neuroglioma during nursing |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105348270A (en) | 2016-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104083364B (en) | A kind of pharmaceutical composition for the treatment of the infantile respiratory tract infection that enterobacter cloacae causes | |
| CN105997990B (en) | Purposes of the compound in the external medicine for suppressing C.perfringens ATCC 13124 is prepared | |
| CN105348270B (en) | A kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp | |
| CN105198903B (en) | A kind of pharmaceutical composition treating acute upper respiratory tract infection | |
| CN105796564B (en) | A kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp | |
| CN106806367A (en) | A kind of pharmaceutical composition for treating infections after burn | |
| CN105085503A (en) | Medicine composition for treating respiratory tract infection | |
| CN105191948B (en) | A kind of control laboratory disinfectant | |
| CN105395538B (en) | A kind of pharmaceutical composition treating acute upper respiratory tract infection | |
| CN105232550B (en) | A kind of pharmaceutical composition treating chronic pelvic inflammatory disease | |
| CN105232542B (en) | A kind of pharmaceutical composition for the treatment of infantile pneumonia | |
| CN105348183A (en) | Pharmaceutical composition for treating gynecology-and-obstetrics postoperative low-fever symptom | |
| CN105748477B (en) | A kind of medicine treating infantile enteritiss | |
| CN105232504B (en) | A kind of pharmaceutical composition for the treatment of infantile respiratory tract infection repeatedly | |
| CN105622619A (en) | Medicine composition for treating periodontitis | |
| CN105853434A (en) | Medicinal composition for treating gingivitis in orthodontic children | |
| CN105287478B (en) | A kind of pharmaceutical composition treating gastritis | |
| CN105061331A (en) | Pharmaceutical composition for eliminating phlegm for children | |
| CN105125546A (en) | Medicine composition for treating postoperative wound infection | |
| CN105294535A (en) | Pharmaceutical composition used for treating pelvic inflammation | |
| CN105237542A (en) | Medicine composition for treating gynecological diseases | |
| CN105560234A (en) | Medicine composition for treating oral and maxillofacial inflammation | |
| CN105601475A (en) | Gingivitis treatment pharmaceutical composition | |
| CN105340896A (en) | Sanitizer for reproductive medicine inspection room | |
| CN105254700A (en) | Medicinal composition for treatment of infection after scald |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180109 Termination date: 20191109 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |